Genmab A/S (GMAB)
29.98
+0.33
(+1.11%)
USD |
NASDAQ |
May 17, 16:00
29.96
-0.02
(-0.07%)
After-Hours: 20:00
Genmab Revenue (Quarterly): 603.46M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 603.46M |
| December 31, 2023 | 675.14M |
| September 30, 2023 | 692.78M |
| June 30, 2023 | 613.55M |
| March 31, 2023 | 408.70M |
| December 31, 2022 | 706.18M |
| September 30, 2022 | 553.31M |
| June 30, 2022 | 452.67M |
| March 31, 2022 | 319.65M |
| December 31, 2021 | 392.83M |
| September 30, 2021 | 366.23M |
| June 30, 2021 | 319.59M |
| March 31, 2021 | 256.29M |
| December 31, 2020 | 327.42M |
| September 30, 2020 | 270.83M |
| June 30, 2020 | 805.00M |
| March 31, 2020 | 131.69M |
| December 31, 2019 | 438.95M |
| September 30, 2019 | 154.93M |
| June 30, 2019 | 116.45M |
| March 31, 2019 | 89.95M |
| December 31, 2018 | 188.92M |
| September 30, 2018 | 93.35M |
| June 30, 2018 | 81.67M |
| March 31, 2018 | 112.35M |
| Date | Value |
|---|---|
| December 31, 2017 | 160.99M |
| September 30, 2017 | 51.12M |
| June 30, 2017 | 114.35M |
| March 31, 2017 | 35.93M |
| December 31, 2016 | 134.48M |
| September 30, 2016 | 54.68M |
| June 30, 2016 | 53.72M |
| March 31, 2016 | 25.16M |
| December 31, 2015 | 84.27M |
| September 30, 2015 | 41.37M |
| June 30, 2015 | 25.74M |
| March 31, 2015 | 16.17M |
| December 31, 2014 | 36.21M |
| September 30, 2014 | 48.28M |
| June 30, 2014 | 21.31M |
| March 31, 2014 | 45.36M |
| December 31, 2013 | 39.42M |
| September 30, 2013 | 26.60M |
| June 30, 2013 | 24.19M |
| March 31, 2013 | 28.28M |
| December 31, 2012 | 28.36M |
| September 30, 2012 | 19.45M |
| June 30, 2012 | 19.28M |
| March 31, 2012 | 16.58M |
| December 31, 2011 | 16.85M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
116.45M
Minimum
Jun 2019
805.00M
Maximum
Jun 2020
430.28M
Average
400.77M
Median
Revenue (Quarterly) Benchmarks
| Ascendis Pharma A/S | 104.16M |
| Novo Nordisk A/S | 9.519B |
| Galecto Inc | -- |
| Evaxion Biotech AS | 0.073M |
| IO Biotech Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 193.00M |
| Total Expenses (Quarterly) | 486.79M |
| EPS Diluted (Quarterly) | 0.2939 |
| Enterprise Value | 15.08B |
| Gross Profit Margin (Quarterly) | 95.53% |
| Profit Margin (Quarterly) | 31.98% |
| Earnings Yield | 4.02% |
| Operating Earnings Yield | 4.19% |
| Normalized Earnings Yield | 3.736 |